Computational Cardiovascular Science aims at the integration of computational methods in cardiovascular research to integrate and expand the information extracted from a range of experimental and clinical data including biosignals and medical images.
Our group is part of the BHF Centre of Research Excellence at Oxford, and includes scientists based at the Department of Computer Science and the Bioengineering Institute, with strong links with the Departments of Cardiovascular Medicine and Physiology, and established collaborations with clinical and experimental collaborators in academia, hospitals, pharmaceutical companies and regulatory agencies.
Translation from basic science to clinical and industrial applications is central to our research. We are also committed to training of postdocs and graduate students in an interdisciplinary, dynamic and flexible research environment to help them acquire the necessary skills for future jobs in academia, industry or government. Our research is currently supported by the Wellcome Trust, the BHF, the European Commission, EPSRC, and we have previously been awarded funding also from the Leverhulme Trust, the Royal Society, the MRC and the BBSRC.
The Computational Cardiovascular Science group is an interdisciplinary team of scientists aiming at translating their background in Engineering, Mathematics, Physics, and Biology to Cardiovascular Research. Each of our teammates has a different range of skill sets and we enjoy combining them to contribute to improving the understanding of the human hearts in health and disease, and to develop new mathematical and computational methodologies for Cardioascular Research. See the team
The National Centre for the Replacement, Refinement & Reduction of Animals in Research (known as NC3Rs) has just awarded £500k to department Professor Blanca Rodriguez on "In Silico human-based methodologies for evaluation of drug safety and efficacy". The award is focused on Blanca's team's research into cardiotoxicity – a major cause of drug attrition in pharmaceutical development and an area where many thousands of animals are used in safety assessment for drug screening purposes or for in vivo studies.
The aim of this award is to accelerate the use of computer simulation in the research of cardiotoxicity and specific cardiac diseases such as myocardial infarction and heart failure. The team includes an impressive list of collaborators including industry and academic scientists, clinicians and regulators from 11 countries. Using data provided by this international network, a database of human cardiac electrophysiology and contractility in computer models will be created. Research evaluation will compare computer model-based human predictions to clinical outcomes, animal data and in vitro models, with the overall aim of building confidence and capacity in computer modelling.
A flexible, robust and easy to use drug safety and efficacy prediction software, for users without specialist programming or mathematical modelling expertise.